Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of TAK-906 in adult symptomatic idiopathic or diabetic gastroparesis
2018-001275-21Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic gastroparesis (IG) and diabetic gastroparesis comparing TAK-906 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in ANMS GCSI-DD composite score. Started Mar 2019; status: completed.
02
Drugs
trazpiroben
03
Conditions
idiopathic gastroparesis (IG)diabetic gastroparesis
Beyond the preview
Go deeper on 2018-001275-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001275-21.